Indigo is a pioneer in developing a continuous multi-metabolite monitoring (CMM®) system for chronic disease management, initially focusing on diabetes through continuous glucose, ketone, and lactate monitoring. The company's nanophotonics technology allows for the implantation of a small sensor under the skin, providing real-time data to aid in disease management.

Wim Pollet

Danaë Delbeke

Indigo Diabetes N.V.

Indigo Diabetes N.V. (Indigo) is a pioneering developer of medical devices for people living with chronic diseases. Using its proprietary nanophotonics technology the Company is developing the world’s first subcutaneously implanted Continuous Multi-Metabolite Monitoring (CMM®)  sensor to provide people living with chronic diseases access to information on their metabolite levels at any time, without the need to wear an external device on their body. Indigo is initially focused on diabetes to address the need for continuous and accurate glucose, ketone, and lactate monitoring.  Indigo is headquartered in Ghent, Belgium, and also has employees based in the US.

Fidimec

Manuardeo

imec.xpand

Ackermans & van Haaren

Parana Management

Qbic Fund

SoFi

Thuja Capital

Titan Baratto

Indigo

Exciting News! 🎉 Thrilled to share that our CEO, Danaë Delbeke, has been recognized among the 100 Most Prominent Women in Belgian Media. 🌟 
Her leadership and impact continue to inspire us all. Congratulations Danaë! 🙌 Check out the full list here: https://lnkd.in/dkZ7UJU7

#leadership  #inspiration #media

Our CEO, Danaë Delbeke, presented at the Life Science Intelligence, Emerging MedTech Summit Europe in September where she talked about our  continuous multi-metabolite monitoring (CMM®) sensor, the only standalone implanted device in development capable of monitoring multiple metabolites continuously.

To watch a replay of her presentation, please follow the link below:
https://lnkd.in/e_eUPVFu

#LSIEurope23 #diabetes #healthcareinnovation 

The Music4Diabetes Consortium launched a new project to improve Type 1 Diabetes treatment by developing an implantable multi-metabolite sensor connected to a pump that delivers insulin continuously.

We are proud to be one of the seven consortium members to be spearheading this project which has already benefitted from a prestigious €3.8m European Innovation Council pathway programme grant.

The new website for the MuSiC4Diabetes project is live! Find out more here: https://lnkd.in/eSqrF6FJ

#MuSiC4Diabetes #DiabetesInnovation #HealthTech #Type1Diabetes #LaunchDay


Today is #worlddiabetesday  with this year’s theme being ‘access to diabetes care’. People with diabetes require ongoing care and support to manage their condition and avoid complications. 
 
That is why at Indigo, we are dedicated to improving the quality of life of people living with diabetes through accurate and continuous glucose, ketone and lactate monitoring. 

Find out more about our technology here: https://lnkd.in/eGtXv8Hm

#worlddiabetesday  #diabetes #medtech #indigo 

Next week, on November 14, is #worlddiabetesday . This year is particularly special as it marks 100 years since scientists, Frederick Banting and John Macleod, were awarded a Nobel Prize in 1923 for the discovery of insulin. 
 
100 years on, we continue to look for advances to help people with diabetes. Indigo’s CMM® implantable sensor monitors multiple metabolites continuously, providing valuable intelligence that can help guide treatment decisions. 

Follow this link to find out more about Indigo Diabetes:  https://indigomed.com

#worlddiabetesday  #diabetesawareness #medtechinnovation 

Metric
Company Name	Indigo Diabetes N.V.
Symbol
MSH ID	COM:INDIGOMED
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Healthcare & Health Services
Country	BE
Stage
Employee Count	48
Website	indigomed.com
LinkedIn	indigomed.com
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:INDIGOMED

Indigo Diabetes N.V.

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue